Story perspectives

Louisiana's Mifepristone Hearing Sparks Telehealth Access Debate

2/25/2026

Summary

Story summary

The hearing on February 24 examines Louisiana's bid to restrict mifepristone by halting mail orders.
The Department of Justice argues plaintiffs lack standing and seeks to pause the case pending the U.S. Food and Drug Administration review.
Advocates say the suit aims to limit telehealth access in underserved areas.
Mifepristone manufacturers push for dismissal of the lawsuit.
Anti-abortion groups back Louisiana, claiming regulations enable coercion in abusive relationships.

1 of 1

Story summary

The hearing on February 24 examines Louisiana's bid to restrict mifepristone by halting mail orders.
The Department of Justice argues plaintiffs lack standing and seeks to pause the case pending the U.S. Food and Drug Administration review.
Advocates say the suit aims to limit telehealth access in underserved areas.
Mifepristone manufacturers push for dismissal of the lawsuit.
Anti-abortion groups back Louisiana, claiming regulations enable coercion in abusive relationships.